We Claim:

1. (S)-2-[[2R,3R,4R,5R]-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydrofuran-2-ylmethoxy]-phenoxy-phosphorylamino]-propionic acid isopropyl ester having the following structure:

![Chemical Structure 1]

or a stereoisomer thereof.

2. The compound as claimed in claim 1 wherein the stereoisomer is (S)-isopropyl 2-[[2R,3R,4R,5R]-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy](phenoxy)phosphoryl)amino)propanoate having following structure:

![Chemical Structure 2]

3. The compound as claimed in claim 1 wherein the stereoisomer is (S)-isopropyl 2-[[2R,3R,4R,5R]-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy](phenoxy)phosphoryl)amino)propanoate having following structure:
4. A composition comprising the compound as claimed in any of the claims 1 to 3, and a pharmaceutically acceptable medium.

5. A process for preparing the compound or a stereoisomer thereof as claimed in claim 1, said process comprising:

reacting a compound $4''$ with a nucleoside analog $5'$

wherein $X'$ is a leaving group.

Dated this the 20th day of October, 2009.

[Signature]

AMRISH TIWARI
OF K&S PARTNERS
ATTORNEY FOR THE APPLICANT
IN-PA/1202